Short Interest in Coloplast A/S Sponsored ADR (OTCMKTS:CLPBY) Grows By 418.6%

Coloplast A/S Sponsored ADR (OTCMKTS:CLPBY) saw a large growth in short interest in the month of May. As of May 15th, there was short interest totaling 413,714 shares, a growth of 418.6% from the April 30th total of 79,768 shares. Currently, 0.0% of the company’s shares are sold short. Based on an average daily volume of 1,160,884 shares, the days-to-cover ratio is currently 0.4 days.

Coloplast A/S Price Performance

OTCMKTS CLPBY remained flat at $6.24 during midday trading on Friday. The company’s stock had a trading volume of 115,347 shares, compared to its average volume of 570,403. The company has a current ratio of 1.30, a quick ratio of 0.81 and a debt-to-equity ratio of 1.50. The stock has a market capitalization of $14.06 billion, a P/E ratio of 44.57, a PEG ratio of 2.02 and a beta of 0.15. The firm has a 50 day simple moving average of $6.54 and a 200-day simple moving average of $7.73. Coloplast A/S has a 1-year low of $6.10 and a 1-year high of $10.03.

Coloplast A/S (OTCMKTS:CLPBY) last announced its earnings results on Tuesday, May 12th. The company reported $0.10 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.09 by $0.01. The business had revenue of $1.11 billion for the quarter, compared to analysts’ expectations of $1.11 billion. Coloplast A/S had a return on equity of 31.96% and a net margin of 7.46%. On average, research analysts predict that Coloplast A/S will post 0.4 earnings per share for the current year.

Analysts Set New Price Targets

Several research firms have commented on CLPBY. The Goldman Sachs Group downgraded Coloplast A/S from a “hold” rating to a “strong sell” rating in a report on Tuesday, April 7th. Kepler Capital Markets upgraded Coloplast A/S to a “strong-buy” rating in a report on Wednesday, May 20th. One equities research analyst has rated the stock with a Strong Buy rating, one has given a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the stock has a consensus rating of “Hold”.

About Coloplast A/S

Coloplast A/S is a global developer and manufacturer of medical devices and services focused on intimate healthcare. The company specializes in solutions designed to assist individuals with chronic medical conditions, aiming to improve quality of life through innovative products. Coloplast’s offerings span ostomy care, continence care, wound and skin care, and interventional urology, targeting patients who require long-term support and specialized treatments.

In its ostomy business, Coloplast provides pouches, skin barriers and accessories for patients who have had surgical procedures to divert bodily waste.